Industry Overview - The cannabis industry has experienced significant growth, with marijuana usage evolving over the years, leading to increased investment opportunities [1][3] - The volatility in marijuana stocks remains high, making it challenging for investors to realize sustainable profits [2][3] Company Highlights Cresco Labs Inc. - Cresco Labs reported a strong Q3 2025, maintaining market dominance and unlocking new growth opportunities [5] - Key financial metrics for Q3 2025 include: - Revenue of $165 million - Operating cash flow of $6 million - Gross profit of $79 million - Adjusted gross profit of $80 million with an adjusted gross margin of 48.8% - SG&A expenses of $52 million, representing 31.3% of revenue - Net loss of $22 million, which includes a $16 million loss from debt extinguishment and $2 million in non-cash impairment charges - Adjusted EBITDA of $40 million with an adjusted EBITDA margin of 24.1% [8] Trulieve Cannabis Corp. - Trulieve operates as a cannabis retailer, cultivating, processing, and distributing cannabis products [9] - On November 4th, Trulieve announced a notice of redemption for all US$368 million of its 8.0% senior secured notes due 2026, which will be delisted from the Canadian Securities Exchange [11] Verano Holdings Corp. - Verano operates as a vertically integrated multi-state cannabis operator in the U.S. [11] - On November 6th, Verano announced an exclusive partnership with Raw Gardens, allowing it to sell Raw Garden-branded products in New Jersey [12]

Core Thesis - Tilray Brands, Inc. is positioned for growth through diversification and international expansion, with a focus on cannabis, beverage, and medical products [2][3][6] Financial Performance - Q4 revenue grew 25% year-over-year to $229.9 million, with beverage sales surpassing cannabis revenue for the first time [2] - Q3 2025 results showed revenue of $209.5 million and non-GAAP breakeven EPS, leading to a 22% intraday share price increase [6] Strategic Initiatives - The company acquired four craft breweries from Molson Coors and introduced new cannabis strains in Canada, indicating a commitment to strategic growth [3] - Tilray expanded its medical cannabis programs and obtained new cultivation and trading licenses in Germany, while launching additional products in Portugal and Canada [2] Market and Regulatory Environment - Political developments in 2024, including potential cannabis deregulation under the Trump administration, created speculation around federal reform [3][5] - Despite Florida voters rejecting a legalization amendment, there is sector-wide optimism regarding easing restrictions and potential banking access for cannabis firms [4] Investor Sentiment - A 14% post-market surge in Tilray shares followed signals from the Trump administration regarding potential cannabis reclassification, renewing investor interest [5] - The company is seen as having a compelling risk/reward profile due to a stronger revenue mix, improving balance sheet, and favorable policy sentiment [6]

Market Trends & Regulatory Landscape - Cannabis stocks have rallied in recent months due to industry-friendly headlines from Washington [1] - The potential rescheduling of cannabis to Schedule 3 by the DEA is being discussed, possibly initiated by an executive order from President Trump [4][5] - Rescheduling could trigger a domino effect, enabling safe banking and major exchange listings for US cannabis companies [11] - Investors remain cautious due to past unfulfilled promises from politicians regarding cannabis reform [6] Investment Opportunities & Risks - US multi-state operators (MSOs) are generating billions in revenue in states with medical or adult-use cannabis programs [9] - These US companies operate contrary to federal law and are unable to list on major US exchanges or access traditional banking services [9] - Advisor Shares Pure US Cannabis ETF (MSOS) specializes in US MSOs, offering a way to invest in these companies [9] - Top picks include Curaleaf, a multi-state operator with hemp beverage interests, and Trulieve, a dominant force in Florida's medical market [12][13] Comparison with Canadian Companies - Canadian cannabis companies like Aurora, Tilray, and Canopy cannot have THC cannabis business in the US but are listed on major US exchanges [8] - US MSOs present a different investment opportunity compared to Canadian companies [13]

Industry Overview - Marijuana stocks are currently in a volatile state with limited upward movement, prompting shareholders to explore various strategies to turn a profit [1] - The lack of federal reform in the U.S. and similar legal frameworks in other global regions are significant barriers, with better laws being essential for recovery [2] - Optimism exists within the industry, as companies are finding ways to maintain operations and profitability despite challenges [2][3] Company Highlights - **Ayr Wellness Inc.**: The company has extended its limited waiver agreement with senior noteholders until July 18, 2025, providing additional time for negotiations and strategic options to strengthen its capital structure [4][6] - **Verano Holdings Corp.**: Recently appointed James Leventis as Chief Strategy and Compliance Officer, aiming to enhance the company's strategic leadership [7][9] - **Glass House Brands Inc.**: Announced preferred equity refinancing on July 16, replacing existing Series B and Series C Preferred Stock with Series E Preferred Stock, effectively canceling the previous series [10][12]